Methotrexate Rosemont Pharmaceuticals (Methotrexate Disodium)

Methotrexate, the active ingredient in Methotrexate Rosemont Pharmaceuticals, is an antimetabolite presented as an oral dosage form for systemic use. It is employed in the management of rheumatoid arthritis, severe psoriasis, and certain leukemias, primarily in adult and pediatric patients as directed by a qualified prescriber.

GNH USA supplies Methotrexate Rosemont Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established distribution networks across Europe, Asia and the Americas, and ensuring regulatory compliance in each market.

Methotrexate is a disease‑modifying antirheumatic drug that interferes with folate metabolism in several inflammatory and malignant conditions. - Rheumatoid arthritis: reduces joint inflammation, pain, and slows structural damage progression. - Psoriasis: decreases skin cell proliferation, leading to improvement of plaque severity and extent. - Acute lymphoblastic leukemia: inhibits leukemic cell growth, contributing to remission when used as part of combination chemotherapy protocols.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or general weakness. - Oral ulcerations or mucositis. - Mild elevation of liver enzymes. - Transient hair thinning. - Decreased white blood cell count.

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Profound bone marrow suppression leading to pancytopenia. - Opportunistic infections due to immunosuppression. - Acute renal failure. - Life‑threatening skin reactions such as Stevens‑Johnson syndrome.

Before initiating therapy, patients should be evaluated for baseline organ function and contraindications. - Monitor liver function: perform regular hepatic enzyme tests. - Assess renal function: adjust dosing if creatinine clearance is reduced. - Conduct complete blood counts: watch for cytopenias. - Avoid use in pregnancy: methotrexate is teratogenic and contraindicated. - Counsel on contraception: effective birth control is required during treatment and for a defined period after discontinuation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Methotrexate can interact with several medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Proton pump inhibitors (e.g., omeprazole): may raise methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: potentiates bone marrow suppression.

Moderate Interactions (Monitor Closely): - Penicillins and other antibiotics: may affect renal clearance. - Live vaccines: immunosuppression can reduce vaccine efficacy. - Alcohol: adds to hepatic stress and toxicity risk.